 |
The Journal of Neuroscience, February 18, 2004, 24(7):1561-1564; doi:10.1523/JNEUROSCI.4650-03.2004
Previous Article | Next Article 
BRIEF COMMUNICATION
Decreased Phosphorylation of NMDA Receptor Type 1 at Serine 897 in Brains of Patients with Schizophrenia
Effat S. Emamian,1,2
Maria Karayiorgou,1 and
Joseph A. Gogos2
1The Rockefeller University, Laboratory of Human Neurogenetics, New York, New York 10021, and 2Columbia University, College of Physicians and Surgeons, Department of Physiology and Cellular Biophysics, Center for Neurobiology and Behavior, New York, New York 10032
NMDA receptor hypofunction in schizophrenia has been inferred by a large number of clinical and preclinical observations; however, whether and how NMDA receptors are exactly involved in the pathogenesis of schizophrenia are still unknown and subject to interpretation. Here we show, in two independent samples of brains from patients with schizophrenia, a significant decrease in the phosphorylation level at serine 897 (S897) of the NMDA receptor type 1 (NR1) subunit. Our finding, together with a previous report that antipsychotics increase phosphorylation of NR1 at S897 in vivo, strongly suggests that insufficient phosphorylation at S897 may contribute to the neuronal pathology underlying schizophrenia.
Key words: schizophrenia; NMDA receptors; NR1; phosphorylation; serine 897; postmortem
Received Oct 14, 2003;
revised December 23, 2003;
accepted December 27, 2003.
This article has been cited by other articles:

|
 |

|
 |
 
B. Li, N. Devidze, D. Barengolts, N. Prostak, E. Sphicas, A. J. Apicella, R. Malinow, and E. S. Emamian
NMDA Receptor Phosphorylation at a Site Affected in Schizophrenia Controls Synaptic and Behavioral Plasticity
J. Neurosci.,
September 23, 2009;
29(38):
11965 - 11972.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al.
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
Pharmacol. Rev.,
September 1, 2008;
60(3):
358 - 403.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Blanke and A. M. J. VanDongen
Constitutive Activation of the N-Methyl-D-aspartate Receptor via Cleft-spanning Disulfide Bonds
J. Biol. Chem.,
August 1, 2008;
283(31):
21519 - 21529.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Blanke and A. M. J. VanDongen
The NR1 M3 Domain Mediates Allosteric Coupling in the N-Methyl-D-aspartate Receptor
Mol. Pharmacol.,
August 1, 2008;
74(2):
454 - 465.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mouri, Y. Noda, A. Noda, T. Nakamura, T. Tokura, Y. Yura, A. Nitta, H. Furukawa, and T. Nabeshima
Involvement of a Dysfunctional Dopamine-D1/N-Methyl-D-aspartate-NR1 and Ca2+/Calmodulin-Dependent Protein Kinase II Pathway in the Impairment of Latent Learning in a Model of Schizophrenia Induced by Phencyclidine
Mol. Pharmacol.,
June 1, 2007;
71(6):
1598 - 1609.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. R. Yang and L. Chen
Targeting Prefrontal Cortical Dopamine D1 and N-Methyl-D-Aspartate Receptor Interactions in Schizophrenia Treatment
Neuroscientist,
October 1, 2005;
11(5):
452 - 470.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
Disease Mechanisms in Neuroscience
Neuroscientist,
August 1, 2004;
10(4):
278 - 279.
[PDF]
|
 |
|
|

|